The extended-spectrum beta-lactamases confer resistance to which antibiotic?

The extended-spectrum beta-lactamases confer resistance to which antibiotic?

• A. Amikacin
• B. Ceftriaxone
• C. Erythromycin
• D. Rifampin

Answer: (B)

Extended-spectrum beta-lactamases inactivate beta-lactam antibiotics by breaking the beta-lactam ring. Ceftriaxone is a third-generation cephalosporin, a type of beta-lactam, so bacteria producing ESBLs are typically resistant to ceftriaxone. The other drugs listed are not beta-lactams (am I kin to amikacin is an aminoglycoside; erythromycin a macrolide; rifampin a rifamycin), so they are not inherently affected by ESBLs through this mechanism. In infections with ESBL producers, ceftriaxone would be ineffective, guiding clinicians toward alternative treatments such as carbapenems.

Extended-spectrum beta-lactamases inactivate beta-lactam antibiotics by breaking the beta-lactam ring. Ceftriaxone is a third-generation cephalosporin, a type of beta-lactam, so bacteria producing ESBLs are typically resistant to ceftriaxone. The other drugs listed are not beta-lactams (am I kin to amikacin is an aminoglycoside; erythromycin a macrolide; rifampin a rifamycin), so they are not inherently affected by ESBLs through this mechanism. In infections with ESBL producers, ceftriaxone would be ineffective, guiding clinicians toward alternative treatments such as carbapenems.